These results suggest that NEK1, C21ORF2 (which is stabilized by NEK1) [48,49], and cyclin F might be elevated in the plasma of ALS patients with mutations in these genes, particularly when the motor neurons of these patients undergo cell death, and thus could serve as biomarkers for patient-specific ALS progression. This evidence concerns the gene NEK1 and amyotrophic lateral sclerosis.